Introduction
Poseidon CRO offers phase II-IV trial management, as well as
all classes of medical device investigations, from
single-center to multi-national projects. With more than 10
years experience of working with majority of indications and
products, our competent, dedicated and flexible study teams
are ready and able to deliver.
We manage projects
from start to finish, but are also happy to work as an
integrated part of your own study team.
The dedicated
and professional Poseidon CRO staff offers a wide range of
academic competence and solid experience of clinical research,
as well as of working with global pharmaceutical and biotech
companies, and of interacting with the various regulatory
authorities in the Nordic region.
All our staff has
medical/scientific backgrounds and continuously undergo
documented training.
Services
The objective is to provide evaluation tools for trial feasibility, in order to:
- Feasibility and Patient Recruitment
- Regulatory and Ethics Committee submissions
- Clinical Monitoring and Site Management
- Project/Study/Site Management
Feasibility and Patient Recruitment
Slow site start up and patient recruitment is the most common
cause of delays in clinical studies, a field of activity in
which every single day , counts.
Our orientation
regionally focused with local CRO with expertise in each
location we cover, our wide-ranging local networks include
investigators both in the private and the public healthcare
system.
We use a well-defined process when selecting
sites, using study-specific questionnaires, thorough
feasibility assessment and evaluation of the potential sites;
all to ensure a high probability of reaching the required
number of patients for the study within the specified
timeline, avoiding confusion and competitive recruitement ,
and minimizing the risks of recruitement failures.
Our
main interventions in this field are :
- To obtain information from a local indication on the feasibility of the clinical trial.
- Identify the environment where the clinical trial will be carried out.
- Identify the targeted population for the recruitment phase of the clinical trial.
- Confirm the timetable of clinical trials processes.
- Make an enlightened decision based on the distribution of sites of the clinical trial.
Regulatory and Ethics Committee submissions and contacts
We handle the regulatory and ethics committee submissions and
contacts in all the covered countries, using our local
experts.
This includes local mandatory regulations,
such as Patient's welfare acts, Personal Data Act and
Radiation Committees regulations.
Our knowledge of
local ethics and regulatory requirements is invaluable in
reducing approval process timelines , which would be long if
additional querries are issued to re assess the submitted
dossier.
Clinical Monitoring and Site Management
Poseidon CRO offer highly experienced Clinical Research
Associates (CRA).
Our project teams collaborate
closely with our sponsors, and maintain close contact with the
sites, supporting each investigator in order to maximize
quality and performance.
Study sites in all the
covered countries are within easy reach of our CRAs,
facilitating coordination and operational efficiency.
Studies
are carried out according to current regulations and
guidelines. Additionally, ICH-GCP, local ethical requirements,
Sponsor's SOPs as well as all procedures and data collected
are subject to our in-house Quality Assurance continuous
support.
Wether it is physical or remote monitoring
, we adopt a risk based approach in identifying with you the
monitoring needs and implement the proper plan and frequency
for each study.
Study Management
Comprehensive project management is the key to the success of
any study.
We have teams of experienced and
well-educated Project Managers present in all covered
countries.
Our Project Managers maintain an overview
of all aspects of the study, working closely with the study
team to ensure control of project scope, quality, budget and
timelines.
All our processes are part of a global
quality management system , spread through out the covered
region and within partner companies to deliver high quality ,
minimising discrepancies , integrating changes and tracking
excellence.
Phase I : Coming soon
Phase II :
Our highly trained team of biostatistics, pharmacology and early phase research experts can proceed to the design of a short-term evaluation of Pharmacokinetics and Pharmacodynamics of your product with mastered protocols of sampling , measuring and analysing data ; allowing a useful insight for the choice of the optimal dose(s) and the search for (drugs/meals)interactions .
Phase III , Patient Retention and interest for research in Emerging Markets Investigators :
Participating in a trial (Phase III) during a multicentric
investigation is what physician researchers look for to back
up their CVs.
The benefit for manufacturers is to
prove their products tolerance and efficacy in the concerned
indication and to be in conformity with MA.
It is
understood that the patients participating in such studies
benefit from free treatment of their pathology, in which
coverage can continue even for two years after the completion
of the clinical trial, under “a compassionate use” programmes
provided by law in majority of areas covered.
Phase IV and Post Marketing Studies :
These studies allow researchers to examine situations concerning the use of drugs on a large scale and will enable to:
- Enrich knowledge of scientific community and regulatory authorities about Pharmacovigilance.
-
Promote medical practitioners’ knowledge of the products and to enable them from building a well-studied attitude of an experienced, analytical user that will impact positively their adoption of the product. -
Dispose of leading patients with medical files used for statistical scientific purposes, research, decision- healthcare policy making or as a support for market planning of manufacturers that lets them be ahead of the competition. -
Post-marketing studies also are an inexhaustible source for data concerning Pharmacovigilance and objective and subjective discretion of a new product by doctors and patients. -
We observe the strictest ethical rules among our entire studies and specifically the post-marketing studies in which investigators are paid for the worthwhile data that they gather and not for the number of participating patients.
The inclusions should imperatively correspond to the targeted medical indications and to forwarded proven statements.
Therapeutic Areas :
Therapeutics Areas | Clinical Phase |
---|---|
Rheumatology | Phase III b, Phase IV |
Haematology-Oncology | Phase IV |
Pneumology | Phase IV |
Hepatology-Virology | Phase IV |
Oncology | Phase II, Phase III |
Neurology | Phase III , Phase IV |
Rare diseases | Phase III |
Cardiology | Phase IV |
Additional Clinical Services
The Donation programmes
To strengthen the brand image and the recognition of the
product among the community of doctors and patients, donation
programmes are addressed to patients without health insurance
coverage, who need therapy and who are not given entitlement
to reimbursement of healthcare costs by local national
medical insurance funds , in many countries of coverage.
We
take care of the programme conceptualisation, implementation
and follow up, along with checking the participants’
eligibility and ensuring the compatibility of drugs through
paying monitoring visits and regular reporting of the
participating centres.
Such a third party approach
gives more consitency to the social responsability of the
manufacturer/importer and permits to gain in confidence among
beneficiaries and health care providers.
Patients’ Access Programs
For specific therapeutics with interlinked
processes(hospitalisation for biotherapy infusion,
anti-cancer chemotherapy, immunosuppressive drug bolus for
patients whose mobility is impaired (MS, etc),we initiate
coordination programmes with patients, prescribing doctors,
social safety organisations and health facilities, so that
the patients’ access to their treatment and drug
administration occurs in optimal conditions.
Particular
knowledge of KOLs (Key Opinion Leaders) for each speciality
and a control of legislations holding the administrative
handling of a drug dispensation and liberation (central
pharmacy , national insurance, ministry of health ...) help
us be catalysts of Market Access for early beneificiaries.
For
all our assistance programmes for patients, a regular update
on access, patients, accountancy of drugs and the mapping of
of prescribing doctors , as well as degree of collaboration
and adoption are provided.
Compliance Reinforcement programmes for special therapeutics
This program is dedicated to patients who are treated for
chronic diseases (hypertension, diabetes , HIV , HCV , CLM
whom are requested to be strictly compliant with the drug
regimen...).
Wether call center based, Web -based , physical
center based ; all our approaches are legislation compliant
and patient centric in order to help them accomplish better
compliance and though better treatment results.
The attending physician benefits from this program
that helps him/her to better follow up these patients during
consultations through accessing an available database
containing historical patients monitoring using a mobile app
, an interactive website or better intellgent blister
technology using NFC tags .
A paramedical trained person accompanies the patient
in local language , throughout the program in a continuous
education perspective to explain for them their illness, the
side effects of drugs and remind them of the time and maaner
of taking the medicines and of any other particular
precautions.